199 related articles for article (PubMed ID: 2081785)
1. Immunotoxins: new therapeutic reagents for autoimmunity, cancer, and AIDS.
Vitetta ES
J Clin Immunol; 1990 Nov; 10(6 Suppl):15S-18S. PubMed ID: 2081785
[TBL] [Abstract][Full Text] [Related]
2. The development of immunotoxins for the therapy of cancer, AIDS, and immune dysfunctions.
Vitetta ES
Princess Takamatsu Symp; 1988; 19():333-40. PubMed ID: 3077626
[TBL] [Abstract][Full Text] [Related]
3. Rationale for clinical use of immunotoxins in cancer and autoimmune disease.
Byers VS; Baldwin RW
Semin Cell Biol; 1991 Feb; 2(1):59-70. PubMed ID: 1954344
[TBL] [Abstract][Full Text] [Related]
4. Immunotoxins containing ricin or its A chain.
Vitetta ES; Thorpe PE
Semin Cell Biol; 1991 Feb; 2(1):47-58. PubMed ID: 1954343
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
[TBL] [Abstract][Full Text] [Related]
6. Immunotoxins in cancer therapy: Review and update.
Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
[TBL] [Abstract][Full Text] [Related]
7. Immunotoxin therapy of cancer.
Frankel AE
Oncology (Williston Park); 1993 May; 7(5):69-78; discussion 79-80, 83-6. PubMed ID: 8512787
[TBL] [Abstract][Full Text] [Related]
8. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
Zovickian J; Johnson VG; Youle RJ
J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171
[TBL] [Abstract][Full Text] [Related]
9. [Possible use of anti-envelope immunotoxins against HIV-infection].
Matsushita S; Koito A; Maeda Y; Hattori T; Takatsuki K
Nihon Rinsho; 1989 Jan; 47(1):220-6. PubMed ID: 2786096
[No Abstract] [Full Text] [Related]
10. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds.
Ramakrishnan S; Bjorn MJ; Houston LL
Cancer Res; 1989 Feb; 49(3):613-7. PubMed ID: 2783383
[TBL] [Abstract][Full Text] [Related]
11. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
Mathew M; Verma RS
Cancer Sci; 2009 Aug; 100(8):1359-65. PubMed ID: 19459847
[TBL] [Abstract][Full Text] [Related]
12. Immunotoxins: a clinical review of their use in the treatment of malignancies.
Hertler AA; Frankel AE
J Clin Oncol; 1989 Dec; 7(12):1932-42. PubMed ID: 2685183
[TBL] [Abstract][Full Text] [Related]
13. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use.
Lambert JM; Goldmacher VS; Collinson AR; Nadler LM; Blättler WA
Cancer Res; 1991 Dec; 51(23 Pt 1):6236-42. PubMed ID: 1718599
[TBL] [Abstract][Full Text] [Related]
14. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
Griffin T; Raso V
Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
[TBL] [Abstract][Full Text] [Related]
15. Immunotoxins.
Press OW
Biotherapy; 1991; 3(1):65-76. PubMed ID: 2009215
[TBL] [Abstract][Full Text] [Related]
16. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
[TBL] [Abstract][Full Text] [Related]
17. Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system.
Webb KS; Poulton SH; Liberman SN; Walther PJ
J Urol; 1989 Aug; 142(2 Pt 1):425-32. PubMed ID: 2787412
[TBL] [Abstract][Full Text] [Related]
18. Immunotoxins: is there a clinical value?
Gottstein C; Winkler U; Bohlen H; Diehl V; Engert A
Ann Oncol; 1994; 5 Suppl 1():97-103. PubMed ID: 7826425
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
20. Immunotoxins: current use and future prospects in bone marrow transplantation and cancer treatment.
Neville DM
Crit Rev Ther Drug Carrier Syst; 1986; 2(4):329-52. PubMed ID: 3549005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
